Brazil Oligo PDP Project Launched

Great news for 5q Spinal Muscular Atrophy (SMA) patients in Brazil! The project proposal from Instituto de Tecnologia em Imunobiológicos (Bio-Manguinhos/Fiocruz), in partnership with Hypera Pharma and Aurisco Pharmaceutical, holder of the generic drug substance (API) technology, will enable Brazil to develop a national platform for manufacturing RNA oligonucleotide-based medicines, including Nusinersen, with the potential to be used in the development of medicines for other genetic diseases.

PDP stands for  Parcerias para o Desenvolvimento Produtivo‌.